Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 20;128(2):259-66.
doi: 10.4103/0366-6999.149226.

Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients

Yi-Cong Ye, Xi-Liang Zhao, Shu-Yang Zhang  1
Affiliations
Review

Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients

Yi-Cong Ye et al. Chin Med J (Engl). .

Abstract

Objective: Statins are still underused for the prevention of cardiovascular disease (CVD) in China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and adverse events of atorvastatin, as well as on patient adherence.

Data sources: We conducted a systemic search in PubMed with the following keywords: "atorvastatin" (Supplementary concept) or "atorvastatin" (All field) and ("China" [AD] or "China" [all field] or "Chinese" [All field]).

Study selection: Clinical or basic research articles on atorvastatin were included.

Results: Atorvastatin is a reversible and competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, decreasing the de novo cholesterol synthesis. The pharmacokinetics of atorvastatin among Chinese is similar to those in Caucasians, and several gene polymorphisms have proved to be associated with the metabolism of atorvastatin in the Chinese population. Several international multiple-center randomized control trials have demonstrated the benefit of atorvastatin for primary and secondary prevention of CVD. None of them, however, included the Chinese, and current evidence in the population is still inadequate, due to the small sample size, low study quality, short study duration, and the use of surrogate endpoints instead of clinical endpoints. The overall incidence of adverse events observed with atorvastatin did not increase in the 10-80 mg dose range, and was similar to that observed with placebo and in patients treated with other statins, which makes atorvastatin well-tolerated in the Chinese population. Moreover, high patient adherence was observed in clinical studies.

Conclusions: Based on the current available evidence, there is no significant difference between Chinese and non-Chinese population in term of pharmacology and clinical efficacy/safety. High-quality evidence is still needed to support the use of atorvastatin in high-risk Chinese population.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Pooled results of safety outcomes for atorvastatin in Chinese population.
See this image and copyright information in PMC

References

    1. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376. - PMC - PubMed
    1. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–81. - PubMed
    1. Cholesterol Treatment Trialists’ (CTT) Collaboration. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. - PMC - PubMed
    1. European Association for Cardiovascular Prevention and Rehabilitation. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. Esc/eas guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (esc) and the european atherosclerosis society (eas) Eur Heart J. 2011;32:1769–818. - PubMed
    1. China Initiative on Clinical Control of Dyslipidemia Expert Group. Expert recommendations on attaining the goal for treatment of hypercholesterolemia in clinical practice. Zhonghua Xin Xue Guan Bing Za Zhi. 2010;38:294–8. - PubMed

MeSH terms